---
company: Altimmune, Inc.
ticker: ALT
form: 8-K
filed: 2026-05-13
accession: 0001326190-26-000037
source: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/
---

# Altimmune (ALT) earnings release, May 13, 2026

Altimmune, Inc. (ALT) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/)

Altimmune Announces First Quarter 2026 Financial Results and Business Update

​

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026

$535 million in cash, cash equivalents and short-term investments as of April 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

GAITHERSBURG, MD – May 13, 2026 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune,” said Jerry Durso, President and Chief Executive Officer of Altimmune. “As a result of the recent successful financing with top-tier biotech investors, we now have a strong cash position that enables us to focus on execution and delivering on our goal of bringing pemvidutide to patients with serious liver diseases and create long-term value for our shareholders. Looking ahead, we have several important milestones this year, including the initiation of the PERFORMA Phase 3 MASH trial, topline data from the RECLAIM Phase 2 AUD trial, and enrollment completion in the RESTORE Phase 2 ALD trial.”

​

Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

​

Alcohol Use Disorder (AUD)

​

Alcohol-associated Liver Disease (ALD)

​

Corporate Update

​

​

​

​

Financial Results for the Three Months Ended March 31, 2026

​

Conference Call Information:

​

Following the conclusion of the call, the webcast will be available for replay on the IR page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is a novel, investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss.

​

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced 48-week data

​

​

​ from the IMPACT Phase 2b trial in MASH. The Phase 2 RECLAIM trial in AUD and RESTORE trial in ALD were initiated in May 2025 and July 2025, respectively, and are currently ongoing.

​

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

​

Follow @Altimmune, Inc. on

LinkedIn

Follow @AltimmuneInc on

X

​

​

​

Forward-Looking Statements

Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including the ongoing RECLAIM and RESTORE trials and planned PERFORMA Phase 3 trial, the timing of key milestones for the Company’s clinical programs, including the anticipated launch of the PERFORMA Phase 3 trial in MASH, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Company’s financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, and the impact of the changes to our leadership and governance structure, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with the SEC, which are available at www.sec.gov.

Investor Contact:

​

Media Contact:

​

​

​

​

## Financial statements

### Income Statement (Three Months Ended — (In thousands, except share and per-share amounts))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 |
|---|---:|---:|
| Revenues | $— | 5 |
| Operating expenses: | Research and development | 16,192 | 15,827 |
| Operating expenses: | General and administrative | 8,052 | 5,993 |
| Operating expenses: | Total operating expenses | 24,244 | 21,820 |
| Operating expenses: | Loss from operations | -24,244 | -21,815 |
| Other income (expense): | Interest expense | -1,068 | -1 |
| Other income (expense): | Interest income | 2,901 | 1,545 |
| Other income (expense): | Other income (expense), net | -152 | 15 |
| Other income (expense): | Total other income (expense), net | 1,681 | 1,559 |
| Other income (expense): | Net loss before income taxes | -22,563 | -20,256 |
| Other income (expense): | Income tax expense (benefit) |  | -681 |
| Other income (expense): | Net loss | -22,563 | -19,575 |
| Other income (expense): | Other comprehensive income — unrealized loss on short-term investments | -296 | -30 |
| Other income (expense): | Comprehensive loss | -22,859 | -19,605 |
| Other income (expense): | Net loss per share, basic and diluted | -0.18 | -0.26 |
| Other income (expense): | Weighted-average common shares outstanding, basic and diluted | 124,461,818 | 75,547,746 |

### Balance Sheet (December 31, — (In thousands, except share and per-share amounts))

| | March 31, – 2026 – (Unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 97,601 | 43,760 |
| Current assets: | Restricted cash | 42 | 42 |
| Current assets: | Total cash, cash equivalents and restricted cash | 97,643 | 43,802 |
| Current assets: | Short-term investments | 233,939 | 229,696 |
| Current assets: | Accounts and other receivables | 1,665 | 1,219 |
| Current assets: | Income tax and R&D incentive receivables |  | 518 |
| Current assets: | Prepaid expenses and other current assets | 1,429 | 2,957 |
| Current assets: | Total current assets | 334,676 | 278,192 |
| Current assets: | Property and equipment, net | 208 | 312 |
| Current assets: | Other assets | 746 | 1,425 |
| Current assets: | Total assets | 335,630 | 279,929 |
| Current liabilities: | Accounts payable | 1,530 | 2,717 |
| Current liabilities: | Accrued expenses and other current liabilities | 9,793 | 12,280 |
| Current liabilities: | Total current liabilities | 11,323 | 14,997 |
| Current liabilities: | Term loan, noncurrent | 34,505 | 34,287 |
| Current liabilities: | Other noncurrent liabilities | 5,815 | 5,753 |
| Current liabilities: | Total liabilities | 51,643 | 55,037 |
| Stockholders’ equity: | Common stock, $0.0001 par value; 200,000,000 shares authorized; 130,221,154 and 110,882,735 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 13 | 11 |
| Stockholders’ equity: | Additional paid-in capital | 961,244 | 879,292 |
| Stockholders’ equity: | Accumulated deficit | -672,046 | -649,483 |
| Stockholders’ equity: | Accumulated other comprehensive loss, net | -5,224 | -4,928 |
| Stockholders’ equity: | Total stockholders’ equity | 283,987 | 224,892 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 335,630 | 279,929 |
